文献速递银屑病与炎症性皮肤病

依奇珠单抗治疗银屑病维持皮肤清除:UNCOVER-3研究三年结果

Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
PubMed 文献 · J Am Acad Dermatol · 2018-05-25

UNCOVER-3研究评估依奇珠单抗(IXE)按推荐剂量方案治疗中重度斑块状银屑病至156周的疗效与安全性。第156周时,采用改良无应答者填补法,80.5%患者达到PASI 75、66.0%达到PASI 90、45.1%达到PASI 100;未发现新的安全性信号。

要点

  • 第156周时,80.5%患者达到PASI 75,66.0%达到PASI 90,45.1%达到PASI 100(改良无应答者填补法)。
  • 基线有头皮、甲或掌跖受累的患者也观察到相似的应答率。
  • 至第3年未发现新的安全性信号。

核心结论

  • 依奇珠单抗可持续维持高应答,实现皮肤和甲病变清除,至3年无新的安全性担忧。

研究设计与样本

  • UNCOVER-3研究,患者随机分配至依奇珠单抗每2周组、依奇珠单抗每4周组、依那西普每周两次组或安慰剂组,在长期扩展期转换为依奇珠单抗每4周治疗。
  • 评估依奇珠单抗按推荐剂量方案(第0周160 mg,至第12周每2周80 mg,此后每4周80 mg)治疗至156周的疗效与安全性。
  • 疗效数据采用观测值分析、多重填补法和改良无应答者填补法进行汇总。

主要发现

  • 第156周时,采用改良无应答者填补法,80.5%患者达到PASI 75,66.0%达到PASI 90,45.1%达到PASI 100。
  • 采用观测值分析和多重填补法,分别有97.2%和86.2%患者达到PASI 75。
  • 基线有头皮、甲或掌跖受累的患者也观察到相似的应答率。
  • 至第3年未发现新的安全性信号。

关键数值与推荐

  • 第156周PASI 75应答率:改良无应答者填补法80.5%,观测值分析97.2%,多重填补法86.2%。
  • 第156周PASI 90应答率:改良无应答者填补法66.0%。
  • 第156周PASI 100应答率:改良无应答者填补法45.1%。

局限性

  • 第12周后无安慰剂或阳性对照比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is a chronic disease that may require long-term treatment. Ixekizumab (IXE), which is a high-affinity monoclonal antibody that selectively targets interleukin 17A, is an approved therapy for patients with moderate-to-severe plaque psoriasis. OBJECTIVE: To evaluate the efficacy and safety of IXE through 156 weeks from the UNCOVER-3 study in patients who were treated with the recommended dose regimen (160 mg of IXE at week 0, 80 mg every 2 weeks up to week 12, and 80 mg every 4 weeks thereafter). METHODS: Patients randomized to IXE every 2 weeks, IXE every 4 weeks, etanercept twice weekly, or placebo were switched to IXE every 4 weeks during the long-term extension period. Efficacy data were summarized by using the as-observed, multiple imputation, and modified nonresponder imputation methods. RESULTS: At week 156, 80.5% of patients had achieved at least a 75% improvement from baseline in their Psoriasis Area Severity Index (PASI) score, 66.0% had achived at least a 90% improvement from baseline in their PASI score, and 45.1% had achieved a 100% improvement from baseline in their PASI score with use of the modified nonresponder imputation method, and 97.2% and 86.2% of patients had achived at least a 75% improvement from baseline in their PASI score with use of the as-observed and multiple imputation methods, respectively. Similar response rates were observed in patients with baseline scalp, nail, or palmoplantar involvement. No new safety signals were identified through year 3. LIMITATIONS: No placebo or active comparison after week 12. CONCLUSION: IXE sustained high responses with clearance of skin and nail lesions, with no new safety concerns through 3 years.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Leonardi C, Maari C, Philipp S, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018. PMID: 29803904. doi:10.1016/j.jaad.2018.05.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。